(Adds details, background)
SHANGHAI, Jan 11 (Reuters) - Merck & Co MRK.N said on
Wednesday it would take legal action against some pharmaceutical
companies after noticing that some manufacturers were supplying
COVID-19 drugs to some provinces and cities saying the medicines
were authorized by Merck.
It did not name the companies in the post on its official
WeChat account in China.
Merck added that Sinopharm 1099.HK is the only legally
authorized distributor of Merck's COVID-19 antiviral
molnupiravir in China, which is sold under the brand name
Lagevrio and was developed by Merck and partner Ridgeback
Biotherapeutics.
It added it had started talks with Sinopharm on the drug's
production technology licence so that Sinopharm can supply the
drug in China. Merck said in September that China National
Biotec Group, an affiliate of Sinopharm, would make the drug.
China's abrupt dismantling of its zero-COVID regime starting
last month has caught its public off-guard, prompting a hospital
scramble for beds and blood and pharmacies to sell out of drugs
as a giant wave of infections hit.
The severe shortage of drugs has made many turn to
underground channels to secure treatments, which has in turn
prompted caution over fake remedies, according to local media
reports and social media posts.
(Reporting by Brenda Goh
Editing by Mark Potter and Jon Boyle)
((brenda.goh@thomsonreuters.com; +86 (0) 21 2083 0088; Reuters
Messaging: brenda.goh.thomsonreuters.com@reuters.net))